董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Ryan | 男 | Director | 77 | 未披露 | 未持股 | 2021-07-13 |
| Sandeep Laumas | 男 | Director | 52 | 15.45万美元 | 2.44 | 2021-07-13 |
| Shalabh Gupta | 男 | Chief Executive Officer, President and Chairman of the Board | 48 | 239.16万美元 | 108.91 | 2021-07-13 |
| Brigitte Schiller | 女 | Director | 61 | 未披露 | 未持股 | 2021-07-13 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John Townsend | 男 | Chief Financial Officer | 59 | 未披露 | 未持股 | 2021-07-13 |
| Shalabh Gupta | 男 | Chief Executive Officer, President and Chairman of the Board | 48 | 239.16万美元 | 108.91 | 2021-07-13 |
| Pramod Gupta | 男 | Executive Vice President, Pharmaceutical and Business Operations | 60 | 103.62万美元 | 17.15 | 2021-07-13 |
董事简历
中英对照 | 中文 | 英文- John Ryan
-
John Ryan，自2011年起担任执行副总裁兼首席医疗官。在加入Kadmon之前，他于2009年至2011年间担任Cerulean Pharma, Inc.（上市制药公司）的高级副总裁兼首席医疗官。在加入Cerulean之前，他于2006年至2009年间担任Aveo Pharmaceuticals, Inc.（上市公司）的首席医疗官。在加入Aveo之前，他是Wyeth（上市特殊制药公司，原名Genetics Institute）的转化性研究高级副总裁，他于1995年至2006年间担任Genetics Institute的实验医学部门主管。他也于1989年至1995年间担任Merck Research Laboratories的临床研究执行主管，此前担任ArQule, Inc.和Expression Analysis, Inc.的科学顾问。他获得了Yale University的学士和博士学位，以及圣地亚哥the University of California的医学博士学位。
John Ryan,has served as our director since 2018. Since 2011 Dr. Ryan has served as Executive Vice President, Chief Medical Officer of Kadmon Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics. From 2009 until 2011 Dr. Ryan served as Senior Vice President and Chief Medical Officer of Cerulean Pharma, Inc., a publicly traded pharmaceutical company, and from 2006 until 2009 he served as Chief Medical Officer at Aveo Pharmaceuticals, Inc. Nasdaq: AVEO, a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. From 1995 until 2006 Dr. Ryan served as Senior Vice President of Translational Research at Wyeth (formerly Genetics Institute), where he served as head of the Department of Experimental Medicine. Dr. Ryan also served as an Executive Director of Clinical Research at Merck Research Laboratories from 1989 to 1995 and he previously served on the scientific advisory boards of ArQule, Inc. and Expression Analysis, Inc. Dr. Ryan has also been a director of Globavir Biosciences, Inc. since 2014. Dr. Ryan received his B.S. and his Ph.D. from Yale University. Dr. Ryan received his M.D. from the University of California, San Diego. - John Ryan，自2011年起担任执行副总裁兼首席医疗官。在加入Kadmon之前，他于2009年至2011年间担任Cerulean Pharma, Inc.（上市制药公司）的高级副总裁兼首席医疗官。在加入Cerulean之前，他于2006年至2009年间担任Aveo Pharmaceuticals, Inc.（上市公司）的首席医疗官。在加入Aveo之前，他是Wyeth（上市特殊制药公司，原名Genetics Institute）的转化性研究高级副总裁，他于1995年至2006年间担任Genetics Institute的实验医学部门主管。他也于1989年至1995年间担任Merck Research Laboratories的临床研究执行主管，此前担任ArQule, Inc.和Expression Analysis, Inc.的科学顾问。他获得了Yale University的学士和博士学位，以及圣地亚哥the University of California的医学博士学位。
- John Ryan,has served as our director since 2018. Since 2011 Dr. Ryan has served as Executive Vice President, Chief Medical Officer of Kadmon Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics. From 2009 until 2011 Dr. Ryan served as Senior Vice President and Chief Medical Officer of Cerulean Pharma, Inc., a publicly traded pharmaceutical company, and from 2006 until 2009 he served as Chief Medical Officer at Aveo Pharmaceuticals, Inc. Nasdaq: AVEO, a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs. From 1995 until 2006 Dr. Ryan served as Senior Vice President of Translational Research at Wyeth (formerly Genetics Institute), where he served as head of the Department of Experimental Medicine. Dr. Ryan also served as an Executive Director of Clinical Research at Merck Research Laboratories from 1989 to 1995 and he previously served on the scientific advisory boards of ArQule, Inc. and Expression Analysis, Inc. Dr. Ryan has also been a director of Globavir Biosciences, Inc. since 2014. Dr. Ryan received his B.S. and his Ph.D. from Yale University. Dr. Ryan received his M.D. from the University of California, San Diego.
- Sandeep Laumas
-
Sandeep Laumas自2021年2月起担任我们的首席财务官，自2020年6月起担任我们的首席商务官。他目前自2020年5月起担任9MetersBiopharma，Inc.董事会成员，此前曾于2014年1月至2020年4月担任执行主席，包括2019年2月至2020年4月担任首席执行官。Laumas博士自2017年9月起担任BioxcelTherapeutics，Inc.董事会成员兼审计委员会主席。Laumas博士在康奈尔大学（Cornell University）获得化学学士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位，他在耶鲁大学医学院（Yale University School of Medicine）完成医学实习。
Sandeep Laumas has served as a director of Company since September 2017. Since June 2020, Dr. Laumas has served as Chief Business Officer and Chief Financial Officer of Instil Bio Inc. He served as a Director of BioXcel Corporation from May 2013 to August 2017. Dr. Laumas served as a director of 9 Meters BioPharma, Inc. (formerly Innovate Biopharmaceuticals Inc.), a biopharma company, from January 2014 to June 2021, including serving as the Executive Chairman from 2014 to April 2020, and as its Chief Executive Officer from February 2019 to April 2020. Dr. Laumas has served as a director of Unicycive Therapeutics Inc. since January 2018. He began his career at Goldman Sachs & Co. in New York in the Investment Banking Division. Dr. Laumas then joined Balyasny Asset Management in New York and later moved to North Sound Capital as a Managing Director responsible for global healthcare investments. He has been investing in healthcare via investment vehicles, Bearing Circle Capital. Dr. Laumas has served as a director of Parkway Holdings Ltd. (IHH Healthcare) and SRL Ltd. Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research gap year at the Dana Farber Cancer Institute and completed his medical internship in 1996 from the Yale University School of Medicine. - Sandeep Laumas自2021年2月起担任我们的首席财务官，自2020年6月起担任我们的首席商务官。他目前自2020年5月起担任9MetersBiopharma，Inc.董事会成员，此前曾于2014年1月至2020年4月担任执行主席，包括2019年2月至2020年4月担任首席执行官。Laumas博士自2017年9月起担任BioxcelTherapeutics，Inc.董事会成员兼审计委员会主席。Laumas博士在康奈尔大学（Cornell University）获得化学学士学位，在奥尔巴尼医学院（Albany Medical College）获得医学博士学位，他在耶鲁大学医学院（Yale University School of Medicine）完成医学实习。
- Sandeep Laumas has served as a director of Company since September 2017. Since June 2020, Dr. Laumas has served as Chief Business Officer and Chief Financial Officer of Instil Bio Inc. He served as a Director of BioXcel Corporation from May 2013 to August 2017. Dr. Laumas served as a director of 9 Meters BioPharma, Inc. (formerly Innovate Biopharmaceuticals Inc.), a biopharma company, from January 2014 to June 2021, including serving as the Executive Chairman from 2014 to April 2020, and as its Chief Executive Officer from February 2019 to April 2020. Dr. Laumas has served as a director of Unicycive Therapeutics Inc. since January 2018. He began his career at Goldman Sachs & Co. in New York in the Investment Banking Division. Dr. Laumas then joined Balyasny Asset Management in New York and later moved to North Sound Capital as a Managing Director responsible for global healthcare investments. He has been investing in healthcare via investment vehicles, Bearing Circle Capital. Dr. Laumas has served as a director of Parkway Holdings Ltd. (IHH Healthcare) and SRL Ltd. Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research gap year at the Dana Farber Cancer Institute and completed his medical internship in 1996 from the Yale University School of Medicine.
- Shalabh Gupta
-
我们的创始人Shalabh Gupta自2016年8月起担任我们的首席执行官，总裁兼董事。自2013年6月以来，Gupta博士还担任Globavir Biosciences，Inc.的创始人兼首席执行官，该公司专注于将治疗全球传染病的新型疗法和强大诊断商业化。Gupta博士还担任过其他各种职务，包括BioCycesive Inc.的创始人兼首席执行官；Genentech，Inc.Genentech Commercial的战略；UBS Investment Bank的股票研究，制药；纽约大学医学中心的主治医师；纽约大学医学院的临床教员；股票研究，Rodman&Renshaw，LLC的生物技术。此外，自2018年以来，他一直服务于Beall Center for Innovation and Entrepreneurship的董事会。自2012年以来，古普塔博士还担任斯坦福大学医学院Spark的顾问，自2013年以来担任TIE的特许成员，TIE是一个由企业家培育创业、指导和教育的非营利网络。Gupta博士此前曾任职Phenome Discoveries Inc.的董事会，是Startup Leadership Program的研究员，Synageva Biopharma Corporation（前身为Avigenics）的医疗顾问，以及纽约大学朗根医疗中心（技术转移办公室）的顾问。Gupta博士在纽约大学RobertF.Wagner公共服务研究生院获得医疗保健财务和管理硕士学位，在印度贾瓦哈拉尔研究生医学教育和研究学院获得医学学位。此外，古普塔博士还完成了他在内科、物理医学和康复医学实习以及纽约大学（纽约大学医学院和纽约大学）心肺康复研究奖学金。他从2000年到2008年在纽约大学的多家医院行医，先是在医学培训期间（2000-2004年），然后是主治医师（2004-2008年）。古普塔博士还担任纽约大学医学院的教师。在过去，古普塔博士是一名董事会认证的医生，他目前持有加州医疗委员会的执照。在华尔街担任股票分析师期间，古普塔博士持有Series7、63、86和87执照。
Shalabh Gupta,our founder, has served as our Chief Executive Officer, President and director since August 2016. Since June 2013 Dr. Gupta has also served as the founder and Chief Executive Officer of Globavir Biosciences, Inc., a company focused on commercializing novel therapeutics and powerful diagnostics for treating global infectious disease. Dr. Gupta has also served in various other capacities including founder and Chief Executive Officer of Biocycive Inc.; Strategy, Genentech Commercial at Genentech, Inc.; Equity Research, Pharmaceuticals at UBS Investment Bank; Attending Physician at NYU Medical Center; clinical faculty member at NYU School of Medicine; and Equity Research, Biotechnology at Rodman & Renshaw, LLC. In addition, he has served on the board of directors of Beall Center for Innovation and Entrepreneurship since 2018. Dr. Gupta has also served as an advisor to SPARK, Stanford University School of Medicine since 2012 a charter member of TiE, a not-for-profit network of entrepreneurs fostering entrepreneurship, mentoring and education, since 2013. Dr. Gupta previously served on the board of directors of Phenomenome Discoveries Inc. and was a Fellow at the Startup Leadership Program, a medical advisor Synageva BioPharma Corporation formerly known as AviGenics and an advisor to NYU Langone Medical Center (Office of Technology Transfer). Dr. Gupta received his MPA in health care finance and management from NYU Robert F. Wagner Graduate School of Public Service, and his medical degree from Jawaharlal Institute of Postgraduate Medical Education & Research, India. Furthermore, Dr. Gupta completed his internship in Internal Medicine, and medical residency in physical medicine and rehabilitation and a research fellowship in cardiopulmonary rehabilitation from New York University (“NYU”) School of Medicine and New York University. He practiced medicine from 2000 to 2008 at NYU’s various hospitals first during his medical training (2000-2004) and then as an attending physician (2004-2008). Dr. Gupta also served as a faculty member at NYU School of Medicine. In the past, Dr. Gupta was a board-certified physician, and he currently holds a license from the California State Medical Board. While working as a stock analyst on Wall Street, Dr. Gupta held Series 7 63 86 and 87 licenses. - 我们的创始人Shalabh Gupta自2016年8月起担任我们的首席执行官，总裁兼董事。自2013年6月以来，Gupta博士还担任Globavir Biosciences，Inc.的创始人兼首席执行官，该公司专注于将治疗全球传染病的新型疗法和强大诊断商业化。Gupta博士还担任过其他各种职务，包括BioCycesive Inc.的创始人兼首席执行官；Genentech，Inc.Genentech Commercial的战略；UBS Investment Bank的股票研究，制药；纽约大学医学中心的主治医师；纽约大学医学院的临床教员；股票研究，Rodman&Renshaw，LLC的生物技术。此外，自2018年以来，他一直服务于Beall Center for Innovation and Entrepreneurship的董事会。自2012年以来，古普塔博士还担任斯坦福大学医学院Spark的顾问，自2013年以来担任TIE的特许成员，TIE是一个由企业家培育创业、指导和教育的非营利网络。Gupta博士此前曾任职Phenome Discoveries Inc.的董事会，是Startup Leadership Program的研究员，Synageva Biopharma Corporation（前身为Avigenics）的医疗顾问，以及纽约大学朗根医疗中心（技术转移办公室）的顾问。Gupta博士在纽约大学RobertF.Wagner公共服务研究生院获得医疗保健财务和管理硕士学位，在印度贾瓦哈拉尔研究生医学教育和研究学院获得医学学位。此外，古普塔博士还完成了他在内科、物理医学和康复医学实习以及纽约大学（纽约大学医学院和纽约大学）心肺康复研究奖学金。他从2000年到2008年在纽约大学的多家医院行医，先是在医学培训期间（2000-2004年），然后是主治医师（2004-2008年）。古普塔博士还担任纽约大学医学院的教师。在过去，古普塔博士是一名董事会认证的医生，他目前持有加州医疗委员会的执照。在华尔街担任股票分析师期间，古普塔博士持有Series7、63、86和87执照。
- Shalabh Gupta,our founder, has served as our Chief Executive Officer, President and director since August 2016. Since June 2013 Dr. Gupta has also served as the founder and Chief Executive Officer of Globavir Biosciences, Inc., a company focused on commercializing novel therapeutics and powerful diagnostics for treating global infectious disease. Dr. Gupta has also served in various other capacities including founder and Chief Executive Officer of Biocycive Inc.; Strategy, Genentech Commercial at Genentech, Inc.; Equity Research, Pharmaceuticals at UBS Investment Bank; Attending Physician at NYU Medical Center; clinical faculty member at NYU School of Medicine; and Equity Research, Biotechnology at Rodman & Renshaw, LLC. In addition, he has served on the board of directors of Beall Center for Innovation and Entrepreneurship since 2018. Dr. Gupta has also served as an advisor to SPARK, Stanford University School of Medicine since 2012 a charter member of TiE, a not-for-profit network of entrepreneurs fostering entrepreneurship, mentoring and education, since 2013. Dr. Gupta previously served on the board of directors of Phenomenome Discoveries Inc. and was a Fellow at the Startup Leadership Program, a medical advisor Synageva BioPharma Corporation formerly known as AviGenics and an advisor to NYU Langone Medical Center (Office of Technology Transfer). Dr. Gupta received his MPA in health care finance and management from NYU Robert F. Wagner Graduate School of Public Service, and his medical degree from Jawaharlal Institute of Postgraduate Medical Education & Research, India. Furthermore, Dr. Gupta completed his internship in Internal Medicine, and medical residency in physical medicine and rehabilitation and a research fellowship in cardiopulmonary rehabilitation from New York University (“NYU”) School of Medicine and New York University. He practiced medicine from 2000 to 2008 at NYU’s various hospitals first during his medical training (2000-2004) and then as an attending physician (2004-2008). Dr. Gupta also served as a faculty member at NYU School of Medicine. In the past, Dr. Gupta was a board-certified physician, and he currently holds a license from the California State Medical Board. While working as a stock analyst on Wall Street, Dr. Gupta held Series 7 63 86 and 87 licenses.
- Brigitte Schiller
-
Brigitte Schiller获委任为董事的提名人，而该委任将于本次发行完成后生效。Schiller博士自2010年起担任Satellite医疗保健的首席医疗官。在这个职位上，席勒博士负责质量、医师领导和研发。她负责质量战略的开发和实施、其执行和组织基础设施。席勒博士担任幕僚长，负责监督80多名医学主任和400多名推荐医生。作为首席营销官，席勒博士负责为美国80个中心的8000多名透析患者提供护理。她指导Satellite’；的临床研究工作，通过深思熟虑的政策，将实用的现实世界研究应用于改善患者体验和结果。在她的领导下，Satellite医疗保健在CMS5Star Ratings中连续多年获得最高质量的评级。过去15年，席勒博士作为研究员参与了多项FDA试验，包括ESRD Care的关键药物和设备试验。她是ESRD护理许多领域的出版作者，包括家庭透析。她被称为鼓舞人心的领导者，决心通过质量改进努力、创新药物和设备以及自1973年以来保持不变的替代护理模式来改变对慢性肾病患者的护理。她一直担任各种早期和成熟的医疗保健公司的顾问。Schiller博士是斯坦福大学肾病学系的兼职讲师。她经常应邀在国家和国际会议上发表演讲。她曾获得教学和研究奖项，包括2017年“女性影响力奖”（Woman of Impact Award）。她是USRDS数据库的专家小组成员。席勒博士以优异成绩毕业于德国弗莱堡大学，除在慕尼黑大学接受研究生培训外，还在拉什-长老会圣卢克医学中心、芝加哥、西北大学和芝加哥大学完成了住院医师和研究奖学金。
Brigitte Schiller,is a nominee for appointment as a director, and such appointment will be effective upon completion of this offering. Dr. Schiller has been Chief Medical Officer at Satellite Healthcare since 2010. In this role, Dr. Schiller is responsible for Quality, Physician Leadership and Research & Development. She oversees the development and implementation of the quality strategy, its execution and organizational infrastructure. Dr. Schiller serves as Chief of Staff, and as such provides oversight on more than 80 medical directors and over 400 referring physicians. As CMO Dr. Schiller is responsible for the delivery of care to more than 8000 dialysis patients in 80 US centers. She directs Satellite’s clinical research efforts, which by deliberate policy are applied pragmatic real-world studies directed towards improvement in patient experience and outcomes. Under her leadership, Satellite Healthcare has achieved the highest quality ratings in the CMS 5 Star Ratings for several years. Dr. Schiller has participated as investigator in multiple FDA trials, including pivotal drug and device trials in ESRD care over the past 15 years. She is a published author in many areas of ESRD care, including home dialysis. She is known as an inspirational leader who is determined to transform the care of patients with chronic kidney disease through quality improvement efforts, innovative drugs and devices as well as alternative care models unchanged since 1973. She has been a consultant to various early-stage and established healthcare companies. Dr. Schiller serves as an Adjunct Lecturer in the Division of Nephrology at Stanford University. She is a frequent invited speaker at national and international meetings. She has received teaching and research awards including the 2017 Woman of Influence award for executives. She serves on the Expert Panel for the USRDS database. Dr. Schiller graduated MD summa cum laude from the University of Freiburg, Germany and, in addition to postgraduate training at the University of Munich, completed residency and research fellowships at Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Northwestern University and the University of Chicago. - Brigitte Schiller获委任为董事的提名人，而该委任将于本次发行完成后生效。Schiller博士自2010年起担任Satellite医疗保健的首席医疗官。在这个职位上，席勒博士负责质量、医师领导和研发。她负责质量战略的开发和实施、其执行和组织基础设施。席勒博士担任幕僚长，负责监督80多名医学主任和400多名推荐医生。作为首席营销官，席勒博士负责为美国80个中心的8000多名透析患者提供护理。她指导Satellite’；的临床研究工作，通过深思熟虑的政策，将实用的现实世界研究应用于改善患者体验和结果。在她的领导下，Satellite医疗保健在CMS5Star Ratings中连续多年获得最高质量的评级。过去15年，席勒博士作为研究员参与了多项FDA试验，包括ESRD Care的关键药物和设备试验。她是ESRD护理许多领域的出版作者，包括家庭透析。她被称为鼓舞人心的领导者，决心通过质量改进努力、创新药物和设备以及自1973年以来保持不变的替代护理模式来改变对慢性肾病患者的护理。她一直担任各种早期和成熟的医疗保健公司的顾问。Schiller博士是斯坦福大学肾病学系的兼职讲师。她经常应邀在国家和国际会议上发表演讲。她曾获得教学和研究奖项，包括2017年“女性影响力奖”（Woman of Impact Award）。她是USRDS数据库的专家小组成员。席勒博士以优异成绩毕业于德国弗莱堡大学，除在慕尼黑大学接受研究生培训外，还在拉什-长老会圣卢克医学中心、芝加哥、西北大学和芝加哥大学完成了住院医师和研究奖学金。
- Brigitte Schiller,is a nominee for appointment as a director, and such appointment will be effective upon completion of this offering. Dr. Schiller has been Chief Medical Officer at Satellite Healthcare since 2010. In this role, Dr. Schiller is responsible for Quality, Physician Leadership and Research & Development. She oversees the development and implementation of the quality strategy, its execution and organizational infrastructure. Dr. Schiller serves as Chief of Staff, and as such provides oversight on more than 80 medical directors and over 400 referring physicians. As CMO Dr. Schiller is responsible for the delivery of care to more than 8000 dialysis patients in 80 US centers. She directs Satellite’s clinical research efforts, which by deliberate policy are applied pragmatic real-world studies directed towards improvement in patient experience and outcomes. Under her leadership, Satellite Healthcare has achieved the highest quality ratings in the CMS 5 Star Ratings for several years. Dr. Schiller has participated as investigator in multiple FDA trials, including pivotal drug and device trials in ESRD care over the past 15 years. She is a published author in many areas of ESRD care, including home dialysis. She is known as an inspirational leader who is determined to transform the care of patients with chronic kidney disease through quality improvement efforts, innovative drugs and devices as well as alternative care models unchanged since 1973. She has been a consultant to various early-stage and established healthcare companies. Dr. Schiller serves as an Adjunct Lecturer in the Division of Nephrology at Stanford University. She is a frequent invited speaker at national and international meetings. She has received teaching and research awards including the 2017 Woman of Influence award for executives. She serves on the Expert Panel for the USRDS database. Dr. Schiller graduated MD summa cum laude from the University of Freiburg, Germany and, in addition to postgraduate training at the University of Munich, completed residency and research fellowships at Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Northwestern University and the University of Chicago.
高管简历
中英对照 | 中文 | 英文- John Townsend
John Townsend自2016年7月起担任财务总监，自2017年3月起担任首席会计官。他在生物技术、医疗设备和高科技电子制造等行业拥有超过20年的上市和私营公司经验。在加入公司之前，Townsend先生在Cosmederm Biosciences，Inc.工作，这是一家专业制药公司。从2005年到2015年，他曾任职Cytori Therapeutics公司（干细胞治疗公司）。从1996年到2005年，他曾任职几家高科技公司，并于1993年从圣地亚哥州立大学（San Diego State University）毕业后在Deloitte公司（原名Deloitte and Touche公司）开始他的职业生涯。Townsend先生是加利福尼亚州的一名注册会计师。
John Townsend,has served as Chief Financial Officer starting in March 2021 and he has previously served as Vice President Finance and Chief Accounting Officer in a consulting role since September 2020. He has over 25 years of public and private company experience in industries including biotechnology, medical devices, and high-tech electronics manufacturing. Before joining the Company, Mr. Townsend worked at Guardion Health Sciences, a medical foods company from 2016 to 2020. From 2005 until 2015 he worked at Cytori Therapeutics, Inc., a stem cell therapy company. From 1996 to 2005 he worked at several high-tech companies, and he started his career at Deloitte formerly Deloitte and Touche after graduating from San Diego State University in 1993. Mr. Townsend is a Certified Public Accountant in the state of California.- John Townsend自2016年7月起担任财务总监，自2017年3月起担任首席会计官。他在生物技术、医疗设备和高科技电子制造等行业拥有超过20年的上市和私营公司经验。在加入公司之前，Townsend先生在Cosmederm Biosciences，Inc.工作，这是一家专业制药公司。从2005年到2015年，他曾任职Cytori Therapeutics公司（干细胞治疗公司）。从1996年到2005年，他曾任职几家高科技公司，并于1993年从圣地亚哥州立大学（San Diego State University）毕业后在Deloitte公司（原名Deloitte and Touche公司）开始他的职业生涯。Townsend先生是加利福尼亚州的一名注册会计师。
- John Townsend,has served as Chief Financial Officer starting in March 2021 and he has previously served as Vice President Finance and Chief Accounting Officer in a consulting role since September 2020. He has over 25 years of public and private company experience in industries including biotechnology, medical devices, and high-tech electronics manufacturing. Before joining the Company, Mr. Townsend worked at Guardion Health Sciences, a medical foods company from 2016 to 2020. From 2005 until 2015 he worked at Cytori Therapeutics, Inc., a stem cell therapy company. From 1996 to 2005 he worked at several high-tech companies, and he started his career at Deloitte formerly Deloitte and Touche after graduating from San Diego State University in 1993. Mr. Townsend is a Certified Public Accountant in the state of California.
- Shalabh Gupta
我们的创始人Shalabh Gupta自2016年8月起担任我们的首席执行官，总裁兼董事。自2013年6月以来，Gupta博士还担任Globavir Biosciences，Inc.的创始人兼首席执行官，该公司专注于将治疗全球传染病的新型疗法和强大诊断商业化。Gupta博士还担任过其他各种职务，包括BioCycesive Inc.的创始人兼首席执行官；Genentech，Inc.Genentech Commercial的战略；UBS Investment Bank的股票研究，制药；纽约大学医学中心的主治医师；纽约大学医学院的临床教员；股票研究，Rodman&Renshaw，LLC的生物技术。此外，自2018年以来，他一直服务于Beall Center for Innovation and Entrepreneurship的董事会。自2012年以来，古普塔博士还担任斯坦福大学医学院Spark的顾问，自2013年以来担任TIE的特许成员，TIE是一个由企业家培育创业、指导和教育的非营利网络。Gupta博士此前曾任职Phenome Discoveries Inc.的董事会，是Startup Leadership Program的研究员，Synageva Biopharma Corporation（前身为Avigenics）的医疗顾问，以及纽约大学朗根医疗中心（技术转移办公室）的顾问。Gupta博士在纽约大学RobertF.Wagner公共服务研究生院获得医疗保健财务和管理硕士学位，在印度贾瓦哈拉尔研究生医学教育和研究学院获得医学学位。此外，古普塔博士还完成了他在内科、物理医学和康复医学实习以及纽约大学（纽约大学医学院和纽约大学）心肺康复研究奖学金。他从2000年到2008年在纽约大学的多家医院行医，先是在医学培训期间（2000-2004年），然后是主治医师（2004-2008年）。古普塔博士还担任纽约大学医学院的教师。在过去，古普塔博士是一名董事会认证的医生，他目前持有加州医疗委员会的执照。在华尔街担任股票分析师期间，古普塔博士持有Series7、63、86和87执照。
Shalabh Gupta,our founder, has served as our Chief Executive Officer, President and director since August 2016. Since June 2013 Dr. Gupta has also served as the founder and Chief Executive Officer of Globavir Biosciences, Inc., a company focused on commercializing novel therapeutics and powerful diagnostics for treating global infectious disease. Dr. Gupta has also served in various other capacities including founder and Chief Executive Officer of Biocycive Inc.; Strategy, Genentech Commercial at Genentech, Inc.; Equity Research, Pharmaceuticals at UBS Investment Bank; Attending Physician at NYU Medical Center; clinical faculty member at NYU School of Medicine; and Equity Research, Biotechnology at Rodman & Renshaw, LLC. In addition, he has served on the board of directors of Beall Center for Innovation and Entrepreneurship since 2018. Dr. Gupta has also served as an advisor to SPARK, Stanford University School of Medicine since 2012 a charter member of TiE, a not-for-profit network of entrepreneurs fostering entrepreneurship, mentoring and education, since 2013. Dr. Gupta previously served on the board of directors of Phenomenome Discoveries Inc. and was a Fellow at the Startup Leadership Program, a medical advisor Synageva BioPharma Corporation formerly known as AviGenics and an advisor to NYU Langone Medical Center (Office of Technology Transfer). Dr. Gupta received his MPA in health care finance and management from NYU Robert F. Wagner Graduate School of Public Service, and his medical degree from Jawaharlal Institute of Postgraduate Medical Education & Research, India. Furthermore, Dr. Gupta completed his internship in Internal Medicine, and medical residency in physical medicine and rehabilitation and a research fellowship in cardiopulmonary rehabilitation from New York University (“NYU”) School of Medicine and New York University. He practiced medicine from 2000 to 2008 at NYU’s various hospitals first during his medical training (2000-2004) and then as an attending physician (2004-2008). Dr. Gupta also served as a faculty member at NYU School of Medicine. In the past, Dr. Gupta was a board-certified physician, and he currently holds a license from the California State Medical Board. While working as a stock analyst on Wall Street, Dr. Gupta held Series 7 63 86 and 87 licenses.- 我们的创始人Shalabh Gupta自2016年8月起担任我们的首席执行官，总裁兼董事。自2013年6月以来，Gupta博士还担任Globavir Biosciences，Inc.的创始人兼首席执行官，该公司专注于将治疗全球传染病的新型疗法和强大诊断商业化。Gupta博士还担任过其他各种职务，包括BioCycesive Inc.的创始人兼首席执行官；Genentech，Inc.Genentech Commercial的战略；UBS Investment Bank的股票研究，制药；纽约大学医学中心的主治医师；纽约大学医学院的临床教员；股票研究，Rodman&Renshaw，LLC的生物技术。此外，自2018年以来，他一直服务于Beall Center for Innovation and Entrepreneurship的董事会。自2012年以来，古普塔博士还担任斯坦福大学医学院Spark的顾问，自2013年以来担任TIE的特许成员，TIE是一个由企业家培育创业、指导和教育的非营利网络。Gupta博士此前曾任职Phenome Discoveries Inc.的董事会，是Startup Leadership Program的研究员，Synageva Biopharma Corporation（前身为Avigenics）的医疗顾问，以及纽约大学朗根医疗中心（技术转移办公室）的顾问。Gupta博士在纽约大学RobertF.Wagner公共服务研究生院获得医疗保健财务和管理硕士学位，在印度贾瓦哈拉尔研究生医学教育和研究学院获得医学学位。此外，古普塔博士还完成了他在内科、物理医学和康复医学实习以及纽约大学（纽约大学医学院和纽约大学）心肺康复研究奖学金。他从2000年到2008年在纽约大学的多家医院行医，先是在医学培训期间（2000-2004年），然后是主治医师（2004-2008年）。古普塔博士还担任纽约大学医学院的教师。在过去，古普塔博士是一名董事会认证的医生，他目前持有加州医疗委员会的执照。在华尔街担任股票分析师期间，古普塔博士持有Series7、63、86和87执照。
- Shalabh Gupta,our founder, has served as our Chief Executive Officer, President and director since August 2016. Since June 2013 Dr. Gupta has also served as the founder and Chief Executive Officer of Globavir Biosciences, Inc., a company focused on commercializing novel therapeutics and powerful diagnostics for treating global infectious disease. Dr. Gupta has also served in various other capacities including founder and Chief Executive Officer of Biocycive Inc.; Strategy, Genentech Commercial at Genentech, Inc.; Equity Research, Pharmaceuticals at UBS Investment Bank; Attending Physician at NYU Medical Center; clinical faculty member at NYU School of Medicine; and Equity Research, Biotechnology at Rodman & Renshaw, LLC. In addition, he has served on the board of directors of Beall Center for Innovation and Entrepreneurship since 2018. Dr. Gupta has also served as an advisor to SPARK, Stanford University School of Medicine since 2012 a charter member of TiE, a not-for-profit network of entrepreneurs fostering entrepreneurship, mentoring and education, since 2013. Dr. Gupta previously served on the board of directors of Phenomenome Discoveries Inc. and was a Fellow at the Startup Leadership Program, a medical advisor Synageva BioPharma Corporation formerly known as AviGenics and an advisor to NYU Langone Medical Center (Office of Technology Transfer). Dr. Gupta received his MPA in health care finance and management from NYU Robert F. Wagner Graduate School of Public Service, and his medical degree from Jawaharlal Institute of Postgraduate Medical Education & Research, India. Furthermore, Dr. Gupta completed his internship in Internal Medicine, and medical residency in physical medicine and rehabilitation and a research fellowship in cardiopulmonary rehabilitation from New York University (“NYU”) School of Medicine and New York University. He practiced medicine from 2000 to 2008 at NYU’s various hospitals first during his medical training (2000-2004) and then as an attending physician (2004-2008). Dr. Gupta also served as a faculty member at NYU School of Medicine. In the past, Dr. Gupta was a board-certified physician, and he currently holds a license from the California State Medical Board. While working as a stock analyst on Wall Street, Dr. Gupta held Series 7 63 86 and 87 licenses.
- Pramod Gupta
Pramod Gupta自2020年9月起担任我们的制药和业务运营执行副总裁，担任咨询职务。古普塔博士是一位有着30年大公司和小公司经验的制药高管。他在全球范围内的药物开发、监管要求和药物审批方面拥有丰富的经验。他通过利用外部合作伙伴关系/技术/业务解决方案，领导了40多个产品的开发/批准/发布。此前，Gupta博士从2011年1月到2018年4月担任Spectrum Pharmaceuticals的高级副总裁，从2005年5月到2009年8月担任Bausch&Lomb的副总裁，并在Baxter，TAP Pharmaceuticals和雅培公司担任越来越多的职位。他发表了50多篇科学论文和2本科学书籍，拥有14项专利。他在新西兰奥塔哥大学完成了博士学位。
Pramod Gupta,has been our Executive Vice President, Pharmaceutical and Business Operations since September 2020 in a consulting role. Dr. Gupta is a pharmaceutical executive with 30 years’ experience at large as well as small companies. He has extensive experience in drug development, regulatory requirements and drug approvals globally. He has led development/approval/launch of over 40 products by leveraging external partnerships/technologies/business solutions. Previously Dr. Gupta served as the Senior Vice President at Spectrum Pharmaceuticals from January 2011 to April 2018 Vice President at Bausch & Lomb from May 2005 to August 2009 and at positions of increasing responsibilities at Baxter, TAP Pharmaceuticals and Abbott Laboratories. He has published more than 50 scientific papers and 2 scientific books, and holds 14 patents. He completed his PhD from the University of Otago New Zealand.- Pramod Gupta自2020年9月起担任我们的制药和业务运营执行副总裁，担任咨询职务。古普塔博士是一位有着30年大公司和小公司经验的制药高管。他在全球范围内的药物开发、监管要求和药物审批方面拥有丰富的经验。他通过利用外部合作伙伴关系/技术/业务解决方案，领导了40多个产品的开发/批准/发布。此前，Gupta博士从2011年1月到2018年4月担任Spectrum Pharmaceuticals的高级副总裁，从2005年5月到2009年8月担任Bausch&Lomb的副总裁，并在Baxter，TAP Pharmaceuticals和雅培公司担任越来越多的职位。他发表了50多篇科学论文和2本科学书籍，拥有14项专利。他在新西兰奥塔哥大学完成了博士学位。
- Pramod Gupta,has been our Executive Vice President, Pharmaceutical and Business Operations since September 2020 in a consulting role. Dr. Gupta is a pharmaceutical executive with 30 years’ experience at large as well as small companies. He has extensive experience in drug development, regulatory requirements and drug approvals globally. He has led development/approval/launch of over 40 products by leveraging external partnerships/technologies/business solutions. Previously Dr. Gupta served as the Senior Vice President at Spectrum Pharmaceuticals from January 2011 to April 2018 Vice President at Bausch & Lomb from May 2005 to August 2009 and at positions of increasing responsibilities at Baxter, TAP Pharmaceuticals and Abbott Laboratories. He has published more than 50 scientific papers and 2 scientific books, and holds 14 patents. He completed his PhD from the University of Otago New Zealand.